Hyperthyroidism medications

Hyperthyroidism medications

Medicine 2CK

Medicine 2CK

Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
HIV and AIDS: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Environmental and chemical toxicities: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Dementia and delirium: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications
Eczematous rashes: Clinical
Papulosquamous skin disorders: Clinical
Alopecia: Clinical
Hypersensitivity skin reactions: Clinical
Autoimmune bullous skin disorders: Clinical
Blistering skin disorders: Clinical
Hypopigmentation skin disorders: Clinical
Benign hyperpigmented skin lesions: Clinical
Skin cancer: Clinical

Transcript

Watch video only

In hyperthyroidism, ‘hyper’ refers to having too much, and ‘thyroid’ refers to thyroid hormones, so hyperthyroidism refers to a condition where there’s excess thyroid hormones.

Medications used to treat hyperthyroidism either reduce the level of thyroid hormones or treat the symptoms by targeting the affected tissue.

There are 2 different thyroid hormones; triiodothyronine or T3, and thyroxine or T4.

Now, if we zoom into the thyroid gland, we’ll find thousands of follicles, which are small, hollow spheres whose walls are lined with follicular cells, or thyrocytes.

Zooming further into these follicular cells, we’ll see their apical side that surrounds a central lumen filled with a viscous fluid called the colloid.

The colloid contains the precursor hormone thyroglobulin.

The basolateral side of follicular cells is in contact with blood vessels that supply these cells.

Synthesis of thyroid hormones begins when follicular cells take in inorganic iodide ions from the blood, along with two sodium ions, via a sodium- iodide symporter.

This step is known as ‘iodide trap’.

The iodide ion is pumped via the pendrin protein, into the viscous fluid inside the follicle called the colloid, which contains thyroglobulin; the precursor of thyroid hormone.

In the colloid, inorganic iodide undergoes oxidation via the enzyme thyroid peroxidase or TPO, to become organic iodide, which then binds to the tyrosine in thyroglobulin.

This step is known as iodination.

Some tyrosine residues bind to only one iodine and form monoiodotyrosine or MIT, whereas others bind to two iodine atoms to form diiodotyrosine or DIT.

These molecules are then coupled together by the same enzyme thyroid peroxidase.

This process is known as coupling.

Coupling one MIT with one DIT creates T3, while coupling 2 DIT molecules creates T4.

T4 is generally created in greater amounts than T3, with T3 being the more active form with a half life of 1 to 2 days, while T4 is less active but has a longer half life of 6 to 8 days.

Once released from the thyroid gland, most of the T3 and T4 travels via the blood by binding with the thyroxine - binding globulin, or TBG, to reach the target cell.

Alternatively, small amounts of T3 and T4 stay unbound, and therefore they are referred to as “free” thyroid hormones.

Only “free” thyroid hormones are physiologically active because they are able to enter the cell.

Now, once inside the cell, T4 is mostly converted into T3 by the enzyme 5’- deiodinase. T3 binds to thyroid hormone receptors which are within the cell’s nucleus, and these receptors regulate gene expression, which ultimately lead to various metabolic and physiologic effects in the body.

This increase in metabolism uses up sugars and fats for energy and produces more body heat.

Thyroid hormones also help activate the sympathetic nervous system which is responsible for the fight or flight response.

This increases heart rate and cardiac output, respiratory rate, and mental alertness.

Thyroid hormones also increase the gastrointestinal or GI motility and they are necessary for normal neuronal development in growing fetuses and young children.

Now, hyperthyroidism can happen in a few different ways.

The most common cause is Graves’ disease, an autoimmune disorder where B cells produce autoantibodies against thyroid stimulating hormone receptors on follicular cells.

These autoantibodies bind to the receptors and activate them, which causes the thyroid follicles to grow and produce more thyroid hormones.

One complication is Graves’ ophthalmopathy which is inflammation and edema in the tissue around the eyes, causing the eyeball to be displaced forwards, eyelids to retract and giving the eyes a “bulgingappearance.

Other disorders like toxic multinodular goiter and thyroiditis can also cause increased release of thyroid hormones.

Now, the symptoms of hyperthyroidism include weight loss despite an increase in appetite because of the higher basal metabolic rate; heat intolerance because the body is producing more heat; and rapid heart rate or tachycardia, sweating, hyperactivity, anxiety and insomnia because of the effect of thyroid hormones on the sympathetic nervous system.

Untreated hyperthyroidism combined with a stressor like an infection or illness can trigger a life- threatening complication called thyroid storm.

Many of the symptoms of hyperthyroidism then become exaggerated, leading to severe tachyarrhythmia, high fever, delirium, and coma.

Now, there are several classes of medications to control hyperthyroidism.

First, we can target the thyroid gland itself, and either decrease the synthesis of thyroid hormones or prevent them from being released.

The other option, at the target tissue peripherally; is to decrease the effectiveness of the thyroid hormones; this only manages the symptoms but doesn’t treat the cause.

Let’s start with the radioactive iodine therapy, also known as “radioiodine ablation therapy”.

The isotope of iodine that is used is I131 .

It’s taken peroral and eventually gets taken up by the thyroid.

Over the course of a few weeks, the radioactive isotope collects in the colloid and emits beta radiation that causes permanent damage to the thyroid.

This is the definitive treatment for hyperthyroidism caused by Graves’ disease and toxic multinodular goiter, but it could also worsen Graves’ ophthalmopathy.

Since the thyroid is permanently destroyed, the person will need to take thyroid hormone replacements like levothyroxine to prevent hypothyroidism.

Radioactive iodine crosses the placenta and is secreted in breast milk, so it should be avoided in people who are pregnant or breastfeeding.

Therefore, administration of radioactive iodine to childbearing individuals requires a negative pregnancy test!

Finally, as far as side effects go, radioactive iodide can cause infertility, thyroiditis, and radiation toxicity, such as neoplasia, hematopoietic suppression, and salivary and lacrimal toxicity.

Next, we have thioamides, which include propylthiouracil, or PTU, and methIMAzole.

Both of these medications are given perorally and are absorbed by the thyroid where they inhibit thyroid peroxidase.

This stops the oxidation of iodide ions into organic iodine, the iodination of tyrosine residues in thyroglobulin, and the coupling of MIT and DIT to form T3 and T4.

It’s important to note that these medications do not inhibit the release of thyroid hormones; therefore they require several weeks until the thyroid depletes its storage of hormones to manifest their therapeutic effect.

In addition, PTU also works in the peripheral tissue by inhibiting 5’- deiodinase to block the conversion of T4 into T3, which makes it the preferred medication during thyroid storms.

Key Takeaways

Hyperthyroidism refers to a condition in which there is excess thyroid hormones. Medications used to treat hyperthyroidism aim at reducing the level of thyroid hormones or the management of associated symptoms. Hyperthyroidism medications include beta blockers, radioactive iodine, propylthiouracil, methimazole, Lugol's iodine, propranolol, and corticosteroids.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Hyperthyroidism: Diagnosis and Treatment" Am Fam Physician (2016)
  5. "Subclinical Hyperthyroidism: When to Consider Treatment" Am Fam Physician (2017)
  6. "Hyperthyroidism" The Lancet (2016)
  7. "THE EFFECT OFD- VERSUSL- PROPRANOLOL IN THE TREATMENT OF HYPERTHYROIDISM" Clinical Endocrinology (1990)
  8. "Increased cancer incidence after radioiodine treatment for hyperthyroidism" Cancer (2007)
  9. "Lugol’s solution and other iodide preparations: perspectives and research directions in Graves’ disease" Endocrine (2017)